WuXi Biologics and GSK enter into licence agreement on multiple T Cell Engagers
WuXi Biologics will receive a $40 million upfront payment and up to $1.46 billion in additional payments for research, development, regulatory and commercial milestones across four TCE antibodies
WuXi Biologics yesterday announced a licence agreement with GSK under which GSK will have exclusive licences for up to four bi- and multi-specific T Cell Engaging (TCE) antibodies developed using WuXi Biologics’ proprietary technology platforms, according to a statement from WuXi Biologics.
Under the agreement, GSK will be granted an exclusive global licence for research, development, manufacturing and commercialisation of a pre-clinical bi-specific antibody that crosslinks tumour cells and T cells by targetting a Tumour-Associated Antigen (TAA) on tumour cells and CD3 expression on T cells and up to three additional pre-clinical TCE antibodies currently at an earlier discovery stage. WuXi Biologics will receive a $40 million upfront payment and up to $1.46 billion in additional payments for research, development, regulatory and commercial milestones across the four TCE antibodies. WuXi Biologics is also eligible to receive tiered royalties on net sales, the statement said.